FDA FY 1992 Appropriations
Bill providing FDA with $ 761.9 mil. cleared the House by a 368-48 vote June 26. The amount is $ 71 mil. more than is appropriated for FY 1991. The bill rejects any assumption that funds would be derived from new user fee programs, reflecting the House Appropriations Committee's criticism of HHS' inclusion of user fees in its budget plan before authorizing legislation is enacted ("The Pink Sheet" June 24, p. 6). . . .
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth